胃轻瘫药物审批:改善阳性结果流程的建议
本文综述了美国胃轻瘫药物审批现状,指出仅甲氧氯普胺获批,需重新评估审批考量。基于流行病学、诊断试验变异及阈值,提出以症状亚量表为终点的4周试验设计,建议将胃轻瘫视为孤儿病并创新监管补充。
要点
- 美国胃轻瘫仅甲氧氯普胺获批,需重新评估药物审批考量。
- 建议以胃轻瘫症状亚量表(如恶心呕吐)为临床终点,而非总症状评分。
- 提出4周治疗试验设计,基于药物作用机制选择特定症状终点。
核心结论
- 证据支持将胃轻瘫视为孤儿病,并创新方法补充监管机构建议。
- 建议4周治疗试验,基于药物机制选择特定症状为临床终点,而非总症状评分。
研究设计与样本
- 文献综述,评估影响胃轻瘫药物审批的流行病学、临床表现、诊断试验变异及阈值等问题。
主要发现
- 美国人群年龄调整患病率(所有类别:明确、可能、疑似)为152,005。
- 主要症状为恶心、呕吐、早饱、餐后饱胀,可能导致住院或急诊就诊。
- 需用至少3小时固体餐闪烁扫描或稳定同位素呼气试验评估胃排空。
- 320千卡真实鸡蛋固体餐的诊断试验重现性、规范数据和变异系数已确立。
关键数值与推荐
- 诊断阈值已针对上述诊断试验建立,320千卡真实鸡蛋固体餐的重现性、规范数据和变异系数已确立。
临床怎么用
- 临床试验可以胃轻瘫症状亚量表(如恶心呕吐)为终点,针对 causative 机制而非潜在动力障碍。
- 新药审批可基于稳健试验中特定改善的症状。
局限性
- 本文为文献综述,未报告原始研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the United States, metoclopramide is the only medication approved for gastroparesis. There is a need to reappraise the main considerations involved in the approval of pharmacological treatments of gastroparesis. OBJECTIVES AND METHODS: We conducted a literature review to address issues that might impact the approval of medications for gastroparesis. We appraised the epidemiology, clinical presentations, variations in diagnostic tests, and their thresholds for identification of gastroparesis. Based on the review, we proposed trial designs for proof of efficacy and safety of novel medications for gastroparesis. RESULTS: Based on epidemiological studies, the age-adjusted prevalence in US population is 152,005 for all categories (definite, probable and possible) of gastroparesis. The major symptoms of gastroparesis are nausea, vomiting, early satiety and postprandial fullness and may lead to hospitalisation or emergency department visits. It is essential to appraise gastric emptying with a solid meal over at least 3 h using scintigraphy or a stable isotope breath test. Diagnostic thresholds have been established for these diagnostic tests and at present, reproducibility, normative data, and coefficient of variation are well established for the 320-kcal real egg solid meal. Based on published guidelines on clinical efficacy of medications used in gastroparesis, we propose targeting the gastroparesis symptom subscales, such as nausea and vomiting, with pharmacological agents specifically directed at their causative mechanisms rather than targeting the underlying dysmotility. CONCLUSION: The evidence documented here justifies consideration of gastroparesis as an orphan disease, as well as an innovative approach to supplement the regulatory bodies' recommendations and guidance to industry. We propose treatment trials of 4-weeks duration and considering the use of specific symptoms of gastroparesis as clinical endpoints based on a pharmaceutical agent's mechanism of action, rather than using a total gastroparesis symptom score. Such an approach would include evidence of safety and efficacy of new medications targeting gastroparesis subscales, and approval for marketing would be based on the symptoms specifically ameliorated in robust trials.
引用
- Camilleri M, Parkman HP. Review Article: Drug Approval for Gastroparesis-Suggestions for Improving the Process for Positive Results. Aliment Pharmacol Ther. 2026. PMID: 41566871. doi:10.1111/apt.70544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。